MacroGenics, Inc (MGNX)

Etorro trading 970x250
MacroGenics, Inc (MGNX) Logo

About MacroGenics, Inc

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. The company’s approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company’s non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. MacroGenics, Inc. has strategic collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Address: 9704 Medical Center Drive, Rockville, MD, United States, 20850

MacroGenics, Inc News and around…

Latest news about MacroGenics, Inc (MGNX) common stock and company :

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
19 Oct, 2021 FinancialContent

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:INDP) from Hold to Buy. Indaptus Therapeutics ...

Wall Street Analysts See a 69% Upside in MacroGenics (MGNX): Can the Stock Really Move This High?
15 Oct, 2021 Yahoo! Finance

The average of price targets set by Wall Street analysts indicates a potential upside of 69.5% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Week In Review: MicroTech Medical Staging $245 Million HK IPO For Diabetes Products
10 Oct, 2021 FinancialContent

MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the price range. LianBio has filed for a $100 million IPO on the Nasdaq exchange.

Zai Lab Says HER2 Drug Meets Endpoints in Bridging Trial
07 Oct, 2021 FinancialContent

Shanghai's Zai Lab reported its in-licensed HER2 drug met its endpoints in patients with previously treated HER2+ breast cancer. Zai acquired China rights to margetuximab as part of a $165 million, three-drug deal from MacroGenics in 2018. MacroGenics was approved to launch margetuximab in the US last year in combination with chemotherapy as a third-line treatment for HER2 positive breast cancer. Zai plans to file a BFA in China before the end of the year. More details.... Stock Symbols: (NSDQ: ZLAB; HKEX: 9688) (NSDQ: MGNX) Share this with colleagues:

Last Week's Notable Insider Buys Included Evergy, Frontier Communications And More
02 Oct, 2021 FinancialContent

Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain. The week's ...

3 Stocks Insiders Are Buying
01 Oct, 2021 FinancialContent

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. ...

Analysts Forecast 19% Upside For The Holdings of FYC
30 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Small Cap Growth AlphaDEX Fund ETF (FYC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $85.79 per unit.

Why Are I-Mab Shares Trading Higher On Tuesday?
28 Sep, 2021 FinancialContent

The Center for Drug Evaluation of China National Medical Products Administrationhas signed offI-Mab's(NASDAQ: ...

Notable Insider Buys Of The Past Week Include Designer Brands, MacroGenics And More
25 Sep, 2021 FinancialContent

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. The ...

Company News for Sep 17, 2021
17 Sep, 2021 Yahoo! Finance

Companies in The News Are: F,WYNN,LVS,MGNX

56 Biggest Movers From Yesterday
17 Sep, 2021 FinancialContent

Check out these big penny stock gainers and losersLosers Vera Therapeutics, Inc. (NASDAQ: VERA) shares tumbled ...

Mid-Afternoon Market Update: Dow Falls 70 Points; Aerie Pharmaceuticals Shares Plunge
16 Sep, 2021 FinancialContent

Toward the end of trading Thursday, the Dow traded down 0.20% to 34,745 while the NASDAQ fell 0.03% to 15,157.61. The S&P also fell, ...

MacroGenics Shares Fall After MGC018 Data Fails To Impress At ESMO Presentation
16 Sep, 2021 FinancialContent

MacroGenics Inc(NASDAQ: MGNX)announced preliminary safety and anti-tumor activity datafrom dose-expansion cohorts of ...

12 Health Care Stocks Moving In Thursday's Intraday Session
16 Sep, 2021 FinancialContent

Gainers Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 27.72% to $2.46 during Thursday's regular session. As ...

Mid-Day Market Update: Gold Drops Over 2%; Leap Therapeutics Shares Jump
16 Sep, 2021 FinancialContent

Midway through trading Thursday, the Dow traded down 0.74% to 34,557.75 while the NASDAQ fell 0.67% to 15,060.25. The S&P also fell, ...

Why MacroGenics Stock Is Tanking Today
16 Sep, 2021 FinancialContent

Investors weren't thrilled with the company's latest clinical data.

38 Stocks Moving In Thursday's Mid-Day Session
16 Sep, 2021 FinancialContent

Gainers IronNet Cybersecurity, Inc. (NASDAQ: IRNT) shares jumped 30.4% to $41.90 amid increased retail investor interest in the ...

Mid-Morning Market Update: Markets Down; US Retail Sales Unexpectedly Increase in August
16 Sep, 2021 FinancialContent

Following the market opening Thursday, the Dow traded down 0.45% to 34,657.69 while the NASDAQ fell 0.66% to 15,061.97. The S&P also ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
16 Sep, 2021 FinancialContent

Gainers Leap Therapeutics (NASDAQ:LPTX) stock rose 32.64% to $2.56 during Thursday's pre-market session. The ...

MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
16 Sep, 2021 FinancialContent
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
16 Sep, 2021 FinancialContent
Notable Monday Option Activity: UBER, SHOO, MGNX
13 Sep, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Uber Technologies Inc (UBER), where a total of 194,577 contracts have traded so far, representing approximately 19.5 million underlying shares. That amounts to about 92.9% of UBER's average daily trading volume over the past month of 20.9 million shares..

Bullish Two Hundred Day Moving Average Cross - MGNX
13 Sep, 2021 FinancialContent

In trading on Monday, shares of MacroGenics, Inc (MGNX) crossed above their 200 day moving average of $25.86, changing hands as high as $26.44 per share. MacroGenics, Inc shares are currently trading up about 5.3% on the day..

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
12 Sep, 2021 FinancialContent
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
12 Sep, 2021 FinancialContent

Biotech stocks retreated in the holiday-shortened week endingSept. 10, reversing course from the previous week. Humanigen, Inc. ...

MacroGenics (MGNX) Stock Jumps 8.9%: Will It Continue to Soar?
10 Sep, 2021 Yahoo! Finance

MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Why MacroGenics Soared Nearly 9% Higher Today
09 Sep, 2021 FinancialContent

Investors are signaling hope in the company's top drug, despite a disappointing final analysis.

MacroGenics Stumbles As Fully Approved Cancer Drug Flops In Roche Rivalry
08 Sep, 2021 Yahoo! Finance

A fully approved breast cancer drug from MacroGenics failed to pass muster in a final analysis, and MGNX stock dipped Wednesday.

MacroGenics Stock Dives As Cancer Drug Shows Mixed Results Vs. Roche Blockbuster
08 Sep, 2021 FinancialContent

A fully approved breast cancer drug from MacroGenics failed to pass muster in a final analysis, and MGNX stock dipped Wednesday.

The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
08 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

MacroGenics, Inc (MGNX) is a NASDAQ Common Stock listed in , ,

970x250